28 Day Repeat Dose in Cystic Fibrosis Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

September 28, 2009

Primary Completion Date

December 29, 2010

Study Completion Date

December 29, 2010

Conditions
Cystic Fibrosis
Interventions
DRUG

SB656933

20 mg

DRUG

SB656933

50mg

DRUG

Placebo

placebo

Trial Locations (33)

12208

GSK Investigational Site, Albany

13353

GSK Investigational Site, Berlin

15213

GSK Investigational Site, Pittsburgh

19104

GSK Investigational Site, Philadelphia

22763

GSK Investigational Site, Hamburg

30322

GSK Investigational Site, Atlanta

31096

GSK Investigational Site, Haifa

33604

GSK Investigational Site, Pessac

34295

GSK Investigational Site, Montpellier

35233

GSK Investigational Site, Birmingham

44106

GSK Investigational Site, Cleveland

44308

GSK Investigational Site, Akron

44791

GSK Investigational Site, Bochum

45122

GSK Investigational Site, Essen

45229

GSK Investigational Site, Cincinnati

49202

GSK Investigational Site, Petah Tikva

51092

GSK Investigational Site, Reims

53226

GSK Investigational Site, Milwaukee

59037

GSK Investigational Site, Lille

60590

GSK Investigational Site, Frankfurt am Main

60637

GSK Investigational Site, Chicago

72076

GSK Investigational Site, Tübingen

75679

GSK Investigational Site, Paris

77030

GSK Investigational Site, Houston

80206

GSK Investigational Site, Denver

85724

GSK Investigational Site, Tucson

91240

GSK Investigational Site, Jerusalem

94304

GSK Investigational Site, Palo Alto

01655

GSK Investigational Site, Worcester

05446

GSK Investigational Site, Colchester

53792-9988

GSK Investigational Site, Madison

M5B 1W8

GSK Investigational Site, Toronto

H2W 1T8

GSK Investigational Site, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY